Kiromic Biopharma, Inc. — Net Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/44364fe6-643c-4d25-93b3-d839b3685bdc/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-26.9M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-004000 |
| FY 2023 | $-20.9M | 2023-01-01 – 2023-12-31 | evidence 0001437749-25-004000 |
| FY 2022 | $-34.7M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-006085 |
| FY 2021 | $-25.6M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-005217 |
| FY 2020 | $-19.2M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003774 |
| FY 2019 | $-3.7M | 2019-01-01 – 2019-12-31 | evidence 0001558370-21-003774 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).